Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. It is built to develop transformative medicines addressing undruggable protein targets driving human disease. It leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides Helicon approach and includes programs targeting two key drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļāļ·āđāļāļāļĢāļīāļĐāļąāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒ- -
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļ- -
āļāļĩāđāļāļĒāļđāđ- -
āđāļĄāļ·āļāļ- -
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđ- -
āļāļĢāļ°āđāļāļĻ- -
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ- -
āđāļāļĢāļĻāļąāļāļāđ- -
āđāļ§āđāļāđāļāļāđ- -
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
Dr. Fawzi Benzaghou, M.D.
Dr. Fawzi Benzaghou, M.D.
Chief Medical Officer
Dr. Helen Ho, Ph.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
Mr. Thomas (Tom) Kotarakos
Mr. Thomas (Tom) Kotarakos
Chief Financial Officer
Mr. Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
Ms. Teresa Jurgensen, J.D.
Ms. Teresa Jurgensen, J.D.
General Counsel
Mr. Alexis Borisy
Lead Independent Director
Lead Independent Director
Mr. Edward M. Fitzgerald
Independent Director
Dr. Mathai Mammen, M.D., Ph.D.
Dr. Mathai Mammen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Dr. Rick Klausner, M.D.
Independent Director
Mr. Alan M. Sebulsky
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Fawzi Benzaghou, M.D.
Dr. Fawzi Benzaghou, M.D.
Chief Medical Officer
Dr. Helen Ho, Ph.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
Mr. Thomas (Tom) Kotarakos
Mr. Thomas (Tom) Kotarakos
Chief Financial Officer
Mr. Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
Ms. Teresa Jurgensen, J.D.
Ms. Teresa Jurgensen, J.D.
General Counsel
Mr. Alexis Borisy
Lead Independent Director
Lead Independent Director